ENTX vs. GNTA, CDTX, LENZ, ALGS, IKNA, AVRO, TSBX, ELUT, ATRA, and TIL
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Genenta Science (GNTA), Cidara Therapeutics (CDTX), LENZ Therapeutics (LENZ), Aligos Therapeutics (ALGS), Ikena Oncology (IKNA), AVROBIO (AVRO), Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.
Genenta Science (NASDAQ:GNTA) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.
Entera Bio has higher revenue and earnings than Genenta Science.
Genenta Science has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.
Entera Bio received 168 more outperform votes than Genenta Science when rated by MarketBeat users. However, 83.33% of users gave Genenta Science an outperform vote while only 66.80% of users gave Entera Bio an outperform vote.
15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 8.9% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Entera Bio has a consensus price target of $10.00, suggesting a potential upside of 308.16%. Given Genenta Science's higher possible upside, analysts plainly believe Entera Bio is more favorable than Genenta Science.
In the previous week, Genenta Science had 3 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Genenta Science and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.79 beat Genenta Science's score of 0.00 indicating that Genenta Science is being referred to more favorably in the media.
Entera Bio's return on equity of 0.00% beat Genenta Science's return on equity.
Summary
Genenta Science beats Entera Bio on 7 of the 12 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
